Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cytokinetics ( (CYTK) ) just unveiled an announcement.
On May 6, 2026, Cytokinetics, Incorporated entered into an underwriting agreement with Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies for a public offering of 9,859,155 shares of its common stock at $71.00 per share. The agreement also included a 30‑day option for the underwriters to buy up to an additional 1,478,873 shares at the same price, which was fully exercised on May 7, 2026.
Cytokinetics reported net proceeds of approximately $760.2 million from the stock offering, after underwriting discounts, commissions and estimated expenses. The transaction, conducted under an automatic shelf registration statement and supported by a legal opinion on the validity of the issued shares, significantly strengthens the company’s capital position to support its ongoing operations and strategic initiatives.
The most recent analyst rating on (CYTK) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.
Spark’s Take on CYTK Stock
According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.
The score is held back primarily by weak financial performance (large losses, significant cash burn, and negative equity), partially offset by a constructive earnings-call outlook driven by a first commercial launch with encouraging early uptake and meaningful regulatory/clinical milestones. Technicals are moderately supportive with the stock trading above major moving averages, while valuation remains challenging given ongoing losses and no dividend.
To see Spark’s full report on CYTK stock, click here.
More about Cytokinetics
Cytokinetics, Incorporated is a biopharmaceutical company focused on developing and commercializing novel muscle biology–driven therapies, with a particular emphasis on cardiovascular and neuromuscular diseases. The company operates in the U.S. life sciences sector and targets patients with serious conditions where there are significant unmet medical needs and substantial market potential.
Average Trading Volume: 2,325,157
Technical Sentiment Signal: Buy
Current Market Cap: $9.24B
See more insights into CYTK stock on TipRanks’ Stock Analysis page.